HC Wainwright Analysts Give Asterias Biotherapeutics (AST) a $11.00 Price Target
HC Wainwright set a $11.00 target price on Asterias Biotherapeutics (NYSEAMERICAN:AST) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts also recently weighed in on AST. Zacks Investment Research raised Asterias Biotherapeutics from a hold rating to a buy rating and set a $1.50 price target for the company in a research report on Tuesday, July 10th. B. Riley set a $6.00 price target on Asterias Biotherapeutics and gave the stock a buy rating in a research report on Friday, August 3rd. Finally, Raymond James downgraded Asterias Biotherapeutics from an outperform rating to a market perform rating in a research report on Friday, August 10th.
NYSEAMERICAN:AST opened at $1.35 on Thursday. Asterias Biotherapeutics has a twelve month low of $1.20 and a twelve month high of $3.74.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.